PLATYPUS – the Australian extension of the OCTOPUS trial
PLATYPUS is the Australian extension of a revolutionary trial based in the United Kingdom (UK) called OCTOPUS, which aims to enroll participants in the UK and Australia over the next few years. OCTOPUS (including PLATYPUS) is a trial which will test multiple treatments with the aim to find one that can slow down, and ultimately […]
Fatigue In Relapsing Multiple Sclerosis – Epstein Barr Virus (FIRMS-EBV) Treatment Trial
Fatigue is a common symptom for many people with MS and it does not respond to traditional MS treatments. It has been suggested that fatigue in MS could relate to chronic infection with the Epstein Barr Virus (EBV). In this clinical trial, two drug therapies with antiviral effects against EBV will be tested for their […]
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS)
Multiple sclerosis (MS) is a potentially devastating disease of the central nervous system and progressive MS, which occurs in up to two-thirds is the most severe form. Current therapies for MS have limited effect in the progressive stage. Recent studies have confirmed that the primary cause of MS is latent infection with Epstein-Barr virus (EBV). […]
The MS Family Study
Researchers from the Menzies Institute for Medical Research are seeking participants who come from families with multiple relatives affected by multiple sclerosis (MS). By analysing the genetic code of such families, the researchers want to better understand the inherited risk of MS.
MS Genetics Project (GEMS Study)
We need your help to investigate the Epstein-Barr Virus (EBV) strain that may play a crucial role in developing multiple sclerosis (MS). This study also aims to identify specific markers in the blood associated with onset and progression of MS. The knowledge gained will be used to greatly improve MS diagnosis, treatment and prevention.
Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS)
The purpose of this study is to improve the quality of care that women with Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) receive while using Assisted Reproductive Technology (ART). We’re inviting women with MS or NMOSD who have already used ART to take part in surveys and interviews to discuss if and where […]
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]
Australian MS Longitudinal Study
The Australian MS Longitudinal Study (AMSLS) is not a clinical trial. It is a survey-based study of life issues, designed to more fully understand the impact of MS, including the individual and overall community impacts. The data from the AMSLS provides a regularly updated, evidence base for a number of stakeholders including health professionals, scientific […]